Quantcast

Latest Protein-bound paclitaxel Stories

2008-10-07 09:00:14

The National Comprehensive Cancer Network (NCCN), Abraxis BioScience (NASDAQ:ABII), and AstraZeneca (NYSE:AZN) today announced that they have entered into a collaboration to conduct multiple investigator-initiated studies of Abraxis BioScience's anti-cancer drug ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound), which is based on the company's proprietary tumor targeting technology known as the nab(TM) platform. The NCCN...

2008-07-18 09:01:12

Biocon and Abraxis BioScience have launched Abraxane in India for the treatment of breast cancer after failure of combination therapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Abraxane is now available in India as a single-use 100mg vial (as a lyophilized powder, to be reconstituted for intravenous administration). In October 2007, Abraxane was approved by the Drug Controller General of India. The approval was based on the clinical trial data that was...

2008-07-18 09:00:20

Biocon Limited, India's pioneering biotechnology company, and Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced the launch of ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India for the treatment of breast cancer after failure of combination therapy for metastatic disease or relapse within six months of adjuvant chemotherapy. ABRAXANE is now available in India as a single-use 100 mg vial (as a...

2008-07-14 12:00:20

Abraxis BioScience has received approval from the China State Food and Drug Administration to market Abraxane paclitaxel for injection for the treatment of breast cancer after failure of standard chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. The Phase III clinical trials in the US and China on which this approval was based demonstrated that Abraxane doubled the response rate, significantly prolonged time to tumor progression, and in the US trial,...

2008-07-14 09:00:14

Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced it has received approval from the China State Food and Drug Administration to market ABRAXANE(R) Paclitaxel for Injection (Albumin Bound) for the treatment of breast cancer after failure of standard chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. The Phase III clinical trials in the U.S. and China on which this approval was based demonstrated that ABRAXANE...

2006-10-30 18:00:29

Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company today announced the launch of the Abraxis Patient Access Program (APAP), a comprehensive patient assistance program for cancer patients being treated with ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). Through APAP, financially eligible cancer patients in need of treatment with ABRAXANE will receive access to the drug at no cost. This new...

2006-04-27 02:15:07

LONDON (Reuters) - Anglo-Swedish drugmaker AstraZeneca Plc said on Thursday it had agreed to sell its U.S. anesthetics and analgesic product portfolio to Abraxis BioScience for $350 million. AstraZeneca said it had also agreed to buy the rights to co-promote breast cancer drug Abraxane in the United States from Abraxis BioScience for $200 million. Europe's third-biggest drugmaker, due to report first-quarter results at 0900 GMT, said the two deals would have a broadly neutral impact...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.